BASKING RIDGE, N.J.
Aug. 14, 2013
/PRNewswire/ -- Mylan Specialty L.P., the fully integrated specialty pharmaceutical business of Mylan Inc. (NASDAQ: MYL), today announced it is continuing the
program. In its first year, more than 20,000 schools across all 50 states participated in the program that offers four free EpiPen or EpiPen Jr
(epinephrine) Auto-Injectors to qualifying schools in the U.S. Qualifications include having a valid prescription.
Over the last year, there has been significant legislative movement across the country to improve access to epinephrine, which should encourage more schools to take advantage of the
program. The goal of the program is to help schools have ready access to epinephrine auto-injectors in case a person experiences a life-threatening allergic reaction (anaphylaxis) at school. People are encouraged to visit
for more information.
"Educating the public about anaphylaxis preparedness and working to improve access to treatment continues to be an important focus at Mylan, which is why we are pleased to be able to extend
, CEO of Mylan. "We hope all schools that have participated in the past will sign up again, and those that haven't yet enrolled in the
program will do so quickly, so that EpiPen Auto-Injectors are in place by the start of the 2013 school year."
Anaphylaxis is unpredictable. For those at risk, it is important to be prepared with an anaphylaxis action plan that includes avoiding known allergens, recognizing the signs and symptoms of anaphylaxis, having immediate access to two epinephrine auto-injectors and seeking immediate emergency medical care should anaphylaxis occur. However, accidental exposure to an allergen can still occur and first-time reactions to unknown allergens are a possibility. Schools should also be prepared with an anaphylaxis action plan.